About Us

D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases. D&D Pharmatech is the parent company of U.S.-based Neuraly Inc., Theraly Fibrosis Inc., and Precision Molecular Inc.

D&D Companies

Building a global biotech company

D&D runs global product development operations via multiple partnerships and owns subsidiaries focused on specific therapeutic areas. D&D is a technology and financing holding company that operates at two primary bases with research and development sites in Korea (Pangyo) and U.S. (Maryland area).

D&D Pharmatech was founded in 2014 in Korea and expanded to the U.S. through research collaborations with multiple scientific co-founders from academia and industry.

NEURALY
Neurology

Neuraly is a clinical-stage company whose mission is to translate scientific discoveries in neurology into revolutionary new drugs that can radically improve and prolong the lives of people suffering from the devasting consequences of diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and other neurodegenerative disorders.

Neuraly was founded in 2016 to translate on the foundational research by world class neuroscientists led by Ted M. Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor and Director of Institute for Cell Engineering at the Johns Hopkins School of Medicine. Neuraly has accumulated a wealth of knowledge in the role of glia biology in neuroinflammation and neuroprotection as well as success in advancing a risk-diversified product portfolio for PD and AD.

NLY01, the lead asset, is a peptide-based drug that targets microglia/astrocytes-induced neuroinflammation and has proven strong therapeutic efficacy in preclinical models of both PD and AD.

PRECISION MOLECULAR
Radiology

Precision Molecular (PMI) is a clinical-stage company with the mission to develop imaging biomarkers and theranostics (targeted therapy combined with diagnostics) for management of patients with CNS disorders and cancer.

PMI was founded in 2019 by Martin G. Pomper, M.D., Ph.D, Henry N. Wagner, Jr. Professor and Director of the Division of Nuclear Medicine and Molecular Imaging at the Johns Hopkins School of Medicine. PMI’s foundational intellectual property was developed by his world class radiology research team, known as the Precision Molecular Imaging Coalition.

PMI features various imaging biomarker products in the clinic with great potential to improve early diagnostics of neurodegenerative diseases and cancer. Utilizing these imaging biomarkers to follow disease progression may provide clinical researchers with powerful tools for early assessment of drug efficacy in clinical trials.

THERALY FIBROSIS
Fibrotic Disease

Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of life-threatening fibrotic disease.

Theraly was founded in 2015 by Seulki Lee, PhD, Associate Professor of Radiology at the Johns Hopkins School of Medicine. Theraly’s founding programs are based on the discoveries of Dr. Lee’s research team, whose pioneering research has elucidated a TRAIL biology pathway underlying the origins of disease in tissue remodeling and fibrosis. The company is focused on developing a potentially universal anti-fibrotic drug.

The lead asset TLY012, a human protein-based drug, selectively targets myofibroblasts, one of the significant originators of fibrosis, and reverses established fibrosis in preclinical models of fibrosis in liver, pancreas, and skin. TLY012 has the potential to cure fibrotic diseases, including systemic sclerosis, liver fibrosis/cirrhosis, and chronic pancreatitis, as well as fibrosis driven cancers.

Other
D&D
Programs

In addition to the companies above, D&D Pharmatech’s drug discovery program is focused on unmet medical needs that include diabetes, obesity and nonalcoholic steatohepatitis (NASH) – conditions affecting millions of people worldwide

Pipeline

Development Stage

Key Founders

Publications

D&D’s commitment to science and cutting-edge research is reflected in our track record of publications. A few recent examples of high impact and high-quality publications co-authored by D&D scientific co-founders and scientists related to our products.

News

Investors

Careers

• D&D Pharmatech is building a powerhouse of innovation led by a team of highly motivated professionals.
  
• We value an attitude of curiosity and creativity towards problem solving as we stride forward with our novel therapies for high unmet medical needs.
  
• We dream of a world where people with severe diseases are living fulfilled lives.
  
• We hope to invite you to our journey of creation.
  
  Contact:HR@ddpharmatech.com